论文 · 体外 / 类器官研究
用pVEC偶联的嵌合反义寡核苷酸靶向细菌TPP核糖开关
Targeting bacterial TPP riboswitches using pVEC-conjugated chimeric antisense oligonucleotides
作者:Dimitrios Kaloudas, Nikolet Pavlova, Martina Traykovska, Robert Penchovsky
Methods Enzymol · 2026年6月22日 · Kaloudas 等 4 位作者
不需要生物学背景,多打比方
正在获取全文并生成讲解(拿不到全文就依据摘要)…
已等待 0 秒大约需要 10–20 秒
可以先看别的,做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来,每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Antisense oligonucleotides (ASOs) provide a sequence-specific approach for targeting bacterial RNAs and suppressing the expression of genes important for bacterial growth and proliferation, making them prominent agents in the design of a novel class of antibacterial agents. This protocol describes the design, preparation, and experimental validation of a chimeric ASO conjugated to the cell-penetrating peptide pVEC and directed against the thiamine pyrophosphate (TPP) riboswitch. The workflow includes bioinformatic identification of conserved and accessible regions within the TPP aptamer, design of a chemically modified ASO, preparation of an in vitro transcribed TPP aptamer RNA substrate, and assessment of ASO-dependent RNA cleavage using an RNase H assay. The protocol further describes bacterial growth-inhibition assays in Listeria monocytogenes and Bacillus subtilis, the use of Escherichia coli as a specificity control, and evaluation of pVEC-ASO-1 cytotoxicity in A549 human cells using an MTT-based viability assay. Although presented for the TPP riboswitch, the approach can be adapted to other bacterial mRNA regions. This protocol therefore provides a flexible experimental framework for evaluating riboswitches and other bacterial RNA elements as potential targets for ASO-based antibacterial development.
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究,以及之后引用它的研究,并说明每篇为什么相关。